Infirst Limited holds intellectual property rights for lipid formulations of NSAIDs for human use in the following 27 countries:


United Kingdom, Germany, France, Spain, Italy, Holland, Denmark, Belgium, Ireland, Sweden, Switzerland, Poland


Unites States, Canada, Mexico, Brazil

Central Asia, Africa and Middle East

India, Israel, Russia, South Africa

Asia Pacific

China, Hong Kong, Japan, Singapore, South Korea


Australia, New Zealand

The company’s aim is to progressively commercialise Flarin in these countries by working with local or regional partners. Interested parties should contact us via enquiries@infirst.co.uk